Amsterdam, 22 June 2009 - Collaboration in prostate cancer translational research in Europe is not only vital to sustain the progress achieved in recent years but also to streamline current efforts between researchers and clinicians and avoid duplication or overlaps. This was amongst the goals of the two-day Prostate Cancer Translational Research in Europe (PCTRE) Meeting which opened today in Amsterdam, The Netherlands.
"It is important that people with research background can communicate with clinicians and vice versa. By doing so we maximise the interaction amongst specialists. It is essential that we show our results to each other," said Prof. Peter Mulders (Nijmegen, The Netherlands), chairman of the European Association of Urology Research Foundation (EAU-RF), organiser of the PCTRE meeting.
With more than 170 participants, the conference opened with lectures and updates on the work of prostate cancer consortia based in Europe. Within the European Community based framework programme these consortia received around 40 million in funding covering scientific topics such as the search for diagnostic and prognostic markers for prostate cancer.
Dr. Thorunn Rafnar (Reykjavic, IS) spoke on the current work regarding the identification of common genetic variants that affect the risk of prostate cancer. 42% of prostate cancer has a genetic cause. The lifetime risk of a man in the European Union to acquire prostate cancer is 10% and it is the third leading cause of death from cancer in men.
"First risk models including low risk variants are appearing," Rafnar said as she added that "the search for genetic determinants of disease severity is ongoing."
Polygene, one of the participating consortia, uses Genome-wide Association studies (see www.genome.gov) to analyse genomes responsible for cancers of the prostate and breast. However, current genetic risk models do not predict who will get progressive disease. Promark, a
|Contact: Lindy Brouwer|
European Association of Urology